Study links delirium and long-term cognitive decline in Alzheimer's patients
August 20, 2012 in Alzheimer's disease & dementia
Patients with Alzheimer's disease who suffered episodes of delirium while hospitalized had a sharply increased rate of mental decline for up to five years after being hospitalized compared to those who did not have any such episodes, according to a study by researchers at The Institute for Aging Research at Hebrew SeniorLife, an affiliate of Harvard Medical School.
The paper, published today in the Archives of Internal Medicine, noted that delirium -- an acute decline in cognitive status, particularly attention and executive function, that typically lasts for a day or several days -- is highly prevalent among Alzheimer's patients who are hospitalized.
"Delirium developed in more than half of the patients we studied," said Alden L. Gross, PhD, MHS, a postdoctoral researcher at the Institute and lead author of the study, the first to examine the significance of the prevalence of delirium over such an extended period of time.
The study showed that patients who had developed delirium during their hospital stays experienced greater cognitive deterioration in the year following the hospitalization than those who had no episodes of delirium and found that mental deterioration proceeded at twice the rate of those who had not suffered such episodes in the year after the hospitalization. Those who suffered episodes of delirium maintained a more rapid rate of cognitive deterioration through up to five years of follow-up.
The researchers studied data collected by the Massachusetts Alzheimer's Disease Research Center on 263 patients. Data on their cognitive status before and after their hospitalizations was evaluated. There was no difference in the rate of cognitive deterioration between the two groups of patients prior to their hospitalizations. The patients were hospitalized for a variety of reasons, including falls, heart issues and other problems.
Alzheimer's is characterized primarily by memory loss. Delirium has typically been considered to be temporary and patients suffering episodes are said to be "out of it" and unable to do tasks requiring sustained concentration such as maintaining or switching attention from one thing to another, according to Gross.
He said the condition is not always recognized by nurses and doctors caring for Alzheimer's patients. "But our research suggests it is an important medical problem," he said.
The sharply increased trajectory of cognitive deterioration on the part of those who had suffered delirium episodes was determined by scores on a number of tests that asked questions having to do with orientation to time, place, current events and other matters.
Gross said the costs of delirium to the health care system are estimated at between $40 billion to $150 billion annually, so it is important that clinicians do a better job of recognizing the condition when it occurs. While strategies to treat delirium when it occurs are still being studied, he said it may be more important to implement proven strategies to prevent it from occurring in the first place, such as the Hospital Elder Life Program.
There are already some things known to help in preventing episodes of delirium while hospitalized, according to Sharon K. Inouye, MD, MPH, director of the Aging Brain Center at Hebrew SeniorLife and senior author on the study, such as making sure patients receive orientation, mobility, nutrition, hydration and sleep. In addition, he said avoiding use of inappropriate medications is important. Finally, environmental factors such as making sure there is light in the room during the day and dark at night and having large clocks in the room can be helpful, she added.
"Strategies to prevent delirium may represent a promising avenue to explore for ameliorating cognitive deterioration in Alzheimer's," the paper concluded.
Journal reference:
JAMA Internal Medicine
Provided by
Hebrew SeniorLife Institute for Aging Research
-
Alzheimer's patients experience adverse outcomes, delirium
Jun 18, 2012 |
not rated yet |
0
-
Delirium may cause rapid cognitive decline in Alzheimer's disease
May 04, 2009 |
not rated yet |
0
-
Relief on the way for delirium patients
May 27, 2011 |
not rated yet |
0
-
Delirium increases risk of developing new dementia eight-fold in older patients
Aug 08, 2012 |
not rated yet |
0
-
Study: delirium presentation predicts mortality
Jul 06, 2009 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Dipole term in multipole expansion
4 hours ago
-
Bubbles in a Pre-Boiling/Boiling pot of water
5 hours ago
-
Assumptions of Griffith's fracture theory
16 hours ago
-
Current leading voltage or vice versa concept
17 hours ago
-
Angular Frequency of AC voltage
21 hours ago
-
Modeling Rigid Body - Unsure about Euler angles and angular velocity
21 hours ago
- More from Physics Forums - Classical Physics
More news stories
Drugs found to both prevent and treat Alzheimer's disease in mice
Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.
Alzheimer's disease & dementia
4 hours ago |
5 / 5 (1) |
0
|
Scientists identify molecular trigger for Alzheimer's disease
Researchers have pinpointed a catalytic trigger for the onset of Alzheimer's disease – when the fundamental structure of a protein molecule changes to cause a chain reaction that leads to the death of neurons ...
Alzheimer's disease & dementia
May 20, 2013 |
5 / 5 (3) |
0
|
Study finds that sleep apnea and Alzheimer's are linked
A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.
Alzheimer's disease & dementia
May 19, 2013 |
5 / 5 (3) |
0
|
Alzheimer's leaves bilingual victims stranded in Canada
The devastating effect of Alzheimer's disease on bilingual people has been thrown into focus in Canada, where the sudden loss of a second language can leave sufferers feeling like strangers in their own country.
Alzheimer's disease & dementia
May 19, 2013 |
not rated yet |
0
Study identifies new approach to improving treatment for MS and other conditions
(Medical Xpress)—Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved ...
Alzheimer's disease & dementia
May 17, 2013 |
5 / 5 (2) |
0
|
New sleeping pill poised to hit US markets
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
Researchers find genetic risk factor for pulmonary fibrosis
A paper recently published in the New England Journal of Medicine and co-written by physicians and scientists at the University of Colorado School of Medicine finds that an important genetic risk factor for pulmonary fibros ...
Biomarkers discovered for inflammatory bowel disease
Using the Department of Defense Serum Repository (DoDSR), University of Cincinnati (UC) researchers have identified a number of biomarkers for inflammatory bowel disease (IBD), which could help with earlier diagnosis and ...
Changing cancer's environment to halt its spread
By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...
Biodegradable stent proves non-inferior to drug-eluting stent
The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent ...
Reducing caloric intake delays nerve cell loss
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...